These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12777544)

  • 1. Counting the shots: a model for immunization screening and referral in nonmedical settings.
    Rickert DL; Shefer AM; Rodewald LE; McCauley MM
    Pediatrics; 2003 Jun; 111(6 Pt 1):1297-302. PubMed ID: 12777544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization coverage levels among 19- to 35-month-old children in 4 diverse, medically underserved areas of the United States.
    Rosenthal J; Rodewald L; McCauley M; Berman S; Irigoyen M; Sawyer M; Yusuf H; Davis R; Kalton G
    Pediatrics; 2004 Apr; 113(4):e296-302. PubMed ID: 15060256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.
    Stein-Zamir C; Israeli A
    Hum Vaccin Immunother; 2017 Sep; 13(9):2102-2110. PubMed ID: 28696824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of up-to-date vaccination status for preschool-aged children: how accurate is manual assessment conducted by paraprofessional staff?
    Shefer A; Webb E; Wilmoth T
    Pediatrics; 2000 Sep; 106(3):493-6. PubMed ID: 10969093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of assessment and referral on immunization coverage in the special supplemental nutrition program for women, infants, and children.
    Ashkar SH; Dales LG; Averhoff F; Shefer A; Higa J; Thompson L; Gomez J; Gee DC; Hurwitz EL
    Arch Pediatr Adolesc Med; 2003 May; 157(5):456-62. PubMed ID: 12742881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and predictors of immunization among inner-city infants: a birth cohort study.
    Brenner RA; Simons-Morton BG; Bhaskar B; Das A; Clemens JD;
    Pediatrics; 2001 Sep; 108(3):661-70. PubMed ID: 11533333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing immunization interventions in the Women, Infants, and Children (WIC) program.
    Thomas TN; Kolasa MS; Zhang F; Shefer AM
    Am J Prev Med; 2014 Nov; 47(5):624-8. PubMed ID: 25217817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007.
    Scheifele DW; Bettinger JA; Halperin SA; Law B; Bortolussi R
    Pediatr Infect Dis J; 2008 Aug; 27(8):755-7. PubMed ID: 18594482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing immunization registry data completeness in Bexar County, Texas.
    Boyd TD; Linkins RW; Mason K; Bulim I; Lemke B
    Am J Prev Med; 2002 Apr; 22(3):184-7. PubMed ID: 11897463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination status of children in the Women, Infants, and Children (WIC) Program: are we doing enough to improve coverage?
    Shefer AM; Luman ET; Lyons BH; Coronado VG; Smith PJ; Stevenson JM; Rodewald LE
    Am J Prev Med; 2001 May; 20(4 Suppl):47-54. PubMed ID: 11331132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
    Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
    JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
    Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.